BrainCheck vs Creyos (2026)
Two digital cognitive assessment platforms for clinicians, and the difference is what each one is selling around the test. BrainCheck is the more complete clinical product. Its flagship is a Class II, 510(k) exempt computerised cognitive assessment aid, and the company states that position plainly, which is rarer than it should be. It publishes reimbursement detail that tells a practice how the work gets paid for, names live integrations with Epic and athenahealth, and carries a product level validation study. Creyos comes from Cambridge Brain Sciences and brings the deepest instrument heritage in this pairing: the underlying tasks appear in more than four hundred peer reviewed studies. It delivers as a link the patient completes at home or in clinic, and it reaches past cognition into behavioral health questionnaires. The common weakness is what sits behind the claims. Neither publishes a price, both name a security attestation without showing it, and Creyos's published privacy policy excludes the patient data the product handles. Ask both for the report and the agreement before the demo.
- The regulatory position is stated completely: BrainCheck Assess is a Class II, 510(k) exempt computerised cognitive assessment aid, indicated as an aid rather than as a diagnosis.
- The reimbursement side is published in unusual detail, which is the part a practice has to model before adopting cognitive testing at all.
- Named live integrations with Epic and athenahealth put the assessment order and the result in the chart rather than beside it.
- The instrument itself carries an exceptional research base, with the underlying tasks used in more than four hundred peer reviewed studies.
- Delivery is a link: the clinician sends an assessment, the patient completes it in clinic or at home on a desktop or tablet, and a report comes back.
- Coverage reaches past cognition into behavioral health questionnaires, so one platform serves two assessment needs.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BrainCheck and Creyos are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BrainCheck | Creyos |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | 2015 | 2009 |
| Headquarters | Austin, Texas, United States | Toronto, Ontario, Canada |
| Website | braincheck.com | creyos.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
BrainCheck
-
Product / capability
BrainCheck added BrainCheck Screen, a pre screening tool that identifies which patients need fuller cognitive testing.
Source
Creyos
-
Clinical evidence
Creyos announced real-world outcomes from its deployment across more than 35 sites at Claremedica, a value-based primary care organization serving over 34,000 Medicare Advantage patients.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Digital cognitive assessment and care planning platform. The flagship product, BrainCheck Assess, is a Class II, 510(k)-exempt computerized cognitive assessment aid regulated by the FDA, indicated as an aid in the assessment of cognitive impairment and explicitly not intended as a standalone diagnostic tool.
Source: AI Health Index, September 2026
Creyos, formerly Cambridge Brain Sciences and briefly Creyos Health, is a Toronto company selling digital cognitive and behavioral health assessment to clinicians. The platform administers twelve short computerized tasks, each mapped to a named cognitive domain covering memory, attention, reasoning, verbal ability and planning, and scores a patient against a normative database the company states holds more than 85,000 participants.
Source: AI Health Index, September 2026
Questions buyers ask
How do BrainCheck and Creyos work with the EHR?
For BrainCheck, the named list stops at those two, and the company notes some feature availability is determined by EHR integration, meaning capability varies by platform.
With Creyos, the consequences are getting larger rather than smaller as the product grows. Cognitive screening during an annual wellness visit produces a result that has to be documented to be billed, and the company markets to payers on diagnosis capture and risk adjustment coding, both of which depend on the finding reaching the record. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
How do BrainCheck and Creyos handle patient data?
Assessment data is handled under role based access controls with activity logging, encrypted in transit and at rest, and BrainCheck states that retention and deletion can be aligned to customer contractual requirements.
For Creyos, the published policy states in terms that it does not apply to protected health information, that the customer's collection and use of that information is governed by the customer's own notice of privacy practices, and that the company's collection and use of it is governed by the customer agreement. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
What evidence is published for BrainCheck and Creyos?
With BrainCheck, a later analysis found a Pearson correlation of 0.77 against the Montreal Cognitive Assessment with a confidence interval reported. A 529 participant study across four United States clinical sites, run with BrainBox Solutions and registered as NCT04423198, tested test retest reliability and concurrent validity against the corresponding paper instruments.
In Creyos' case, the instrument level evidence is exceptional. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
How much do BrainCheck and Creyos leave to the clinician?
For BrainCheck, the company states that the assessment is not intended for use as a standalone diagnostic tool, that it is designed to support clinical interpretation rather than replace it, and that structured cognitive data is meant to be read alongside history, examination findings and functional status rather than in isolation.
With Creyos, no published material describes how invalid or assisted attempts are detected or flagged, whether repeated attempts are recorded, or what a clinician sees to tell a clean administration from a compromised one. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Read the evidence claims at the right level on both records. Creyos's research base belongs to the cognitive tasks rather than to the platform sold around them, and the distinction matters when the sales conversation slides from one to the other. BrainCheck's validation study reported at least 88 percent sensitivity and specificity separating normal cognition from impairment, which is a product level result, at a study size a buyer should note.
On assurance, both name attestations and neither shows one: BrainCheck holds HITRUST certification with every artifact behind a request and usually an agreement, and Creyos carries a HIPAA and SOC 2 compliant statement among its headline figures with none of the detail that would let a buyer assess it. Creyos's only published privacy document states that it does not apply to protected health information, which leaves the patient data question routed somewhere a buyer cannot read.
Neither publishes a price. BrainCheck publishes a policy of not enumerating its model supply chain, which is a stated position rather than an omission, and Creyos publishes nothing about its chain at all.